Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study

Allergy. 2020 Mar;75(3):669-672. doi: 10.1111/all.13950. Epub 2019 Oct 23.

Authors

Affiliations

¹ Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
² Institute of Pharmacology, University of Bern, Bern, Switzerland.
³ Centro Studi GISED, Bergamo, Italy.
⁴ Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia.

PMID: 31230371
DOI: 10.1111/all.13950

No abstract available

Keywords: bullous pemphigoid; eosinophil; interleukin-5; mepolizumab.

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Double-Blind Method
Eosinophils
Humans
Interleukin-5
Pemphigoid, Bullous* / drug therapy
Pilot Projects

Substances

Antibodies, Monoclonal, Humanized
Interleukin-5
mepolizumab